NCT07027826

Brief Summary

Background: Eosinophilic esophagitis (EoE) is a disease that causes inflammation in the esophagus. The esophagus is the tube that moves food from the mouth to the stomach. Diagnosing EoE currently requires a specialized tool called an endoscope. The esophageal string test (EST) is another test; the EST collects fluid from the upper digestive tract. An EST is simpler and cheaper than an endoscopy. Researchers want to know if an EST can diagnose EoE. Objective: To test if the EST can diagnose EoE in people who have trouble swallowing. Eligibility: Adults aged 18 to 65 years with trouble swallowing. They must have been born in the African continent or their parents were born in Africa. Design: Participants will be screened. They will give blood, stool, urine, and skin swab samples. They will complete surveys about their medical history, diet, symptoms, and home environment. They will bring a sample of their drinking water for testing. Participants will have an EST. They will swallow a pill capsule that contains a nylon string. One end of the string will be taped to their cheek. The string will unravel down the esophagus and into the stomach. It will be pulled out after 1 hour. Fluids that soaked into the string will be tested. At a different visit, participants will have an endoscopic exam. An endoscope is a flexible tube that is inserted down the mouth; it can be used to take tissue samples from the esophagus, stomach, and small intestine. Participants will have a final visit in person, online, or by phone. They will take a survey and talk about their test results.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
70

participants targeted

Target at P50-P75 for not_applicable

Timeline
16mo left

Started May 2026

Geographic Reach
2 countries

3 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 18, 2025

Completed
1 day until next milestone

First Posted

Study publicly available on registry

June 19, 2025

Completed
11 months until next milestone

Study Start

First participant enrolled

May 11, 2026

Expected
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2027

Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2027

Last Updated

May 6, 2026

Status Verified

April 10, 2026

Enrollment Period

1.3 years

First QC Date

June 18, 2025

Last Update Submit

May 5, 2026

Conditions

Keywords

Eosinophilic EsophagitisDysphagiaEsophageal string test

Outcome Measures

Primary Outcomes (1)

  • Sensitivity and specificity of the esophageal string test to detect Eosinophilic Esophagitis.

    Assess the accuracy of the 1-hour EST as a diagnostic screening tool for EoE in populations with limited access to subspecialty care. Sensitivity and specificity provide a measure of accuracy when compared to the diagnostic gold standard.

    End of study

Secondary Outcomes (1)

  • Proportion of Eosinophilic Esophagitis cases diagnosed in each cohort.

    End of study

Study Arms (1)

Esophageal string test

EXPERIMENTAL

The esophageal string test is a minimally invasive procedure used to collect esophageal secretions for diagnostic analysis.

Device: Esophageal string test

Interventions

The esophageal string test consists of a gelatin or cellulose capsule containing a nylon string. The capsule dissolves allowing the nylon string to absorb esophageal secretions which can be analyzed for various inflammatory mediators.

Esophageal string test

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • In order to be eligible to participate in this study, an individual must meet all of the following criteria:
  • Able to provide informed consent.
  • Aged 18 to 65 years.
  • Born in the African continent or their parents were born in Africa,
  • Exhibiting symptoms of dysphagia and/or prior history of food impaction.
  • Undergoing clinically indicated endoscopy at the NIH Clinical Center (U.S.), Centre Hospitalier Universitaire Gabriel Tour(SqrRoot)(Copyright) (Mali), or other local clinics (Mali) and willing to provide research samples and data.

You may not qualify if:

  • An individual who meets any of the following criteria will be excluded from participation in this study:
  • Recent steroid use (systemic or swallowed/topical corticosteroid) within 4 weeks prior to endoscopy.
  • Recent use of dupilumab (Dupixent) within the last 6 months.
  • Recent use of other biologic medications (within either 6 months or 5 half-lives, whichever is longer). Examples of biologic medications include:
  • a. mepolizumab (Nucala)
  • b. reslizumab (Cinqair, Cinqaero)
  • c. benralizumab (Fasenra)
  • d. cendakimab
  • e. tezepelumab (Tezspire)
  • f. barzolvolimab
  • \. Individuals suffering from a bleeding diathesis (e.g., hemophilia, severe thrombocytopenia).
  • \. Current use of anticoagulant medications.
  • \. Pregnancy.
  • \. Treatment with another investigational drug or other investigational intervention within 6 months or 5 half-lives whichever is longer.
  • \. Individuals with a known history of any of the following:
  • +11 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

RECRUITING

Gabriel Toure University Hospital Center

Bamako, Mali

NOT YET RECRUITING

Mali International Center for Excellence in Research

Bamako, Mali

NOT YET RECRUITING

Related Links

MeSH Terms

Conditions

Deglutition DisordersEosinophilic Esophagitis

Condition Hierarchy (Ancestors)

Esophageal DiseasesGastrointestinal DiseasesDigestive System DiseasesPharyngeal DiseasesOtorhinolaryngologic DiseasesEsophagitisGastroenteritisEosinophiliaLeukocyte DisordersHematologic DiseasesHemic and Lymphatic DiseasesHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Study Officials

  • Gregory M Constantine, M.D.

    National Institute of Allergy and Infectious Diseases (NIAID)

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Gregory M Constantine, M.D.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
NIH
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 18, 2025

First Posted

June 19, 2025

Study Start (Estimated)

May 11, 2026

Primary Completion (Estimated)

August 31, 2027

Study Completion (Estimated)

August 31, 2027

Last Updated

May 6, 2026

Record last verified: 2026-04-10

Data Sharing

IPD Sharing
Will not share

Locations